As of 2025-07-05, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -13.59 mil USD. CARA's TTM EBITDA according to its financial statements is -61.10 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.1x - 10.3x | 8.1x |
| Forward P/E multiples | 11.1x - 17.7x | 14.8x |
| Fair Price | (140.38) - (129.15) | (144.79) |
| Upside | -2738.6% - -2527.5% | -2821.6% |
| Date | EV/EBITDA |
| 2025-05-09 | -1.30 |
| 2025-05-08 | -1.33 |
| 2025-05-07 | -1.32 |
| 2025-05-06 | -1.34 |
| 2025-05-05 | -1.46 |
| 2025-05-02 | -1.38 |
| 2025-05-01 | -1.28 |
| 2025-04-30 | -1.25 |
| 2025-04-29 | -1.10 |
| 2025-04-28 | -0.95 |
| 2025-04-25 | -0.79 |
| 2025-04-24 | -0.71 |
| 2025-04-23 | -0.76 |
| 2025-04-22 | -0.84 |
| 2025-04-21 | -0.69 |
| 2025-04-17 | -0.65 |
| 2025-04-16 | -0.74 |
| 2025-04-15 | -0.57 |
| 2025-04-14 | -0.62 |
| 2025-04-11 | -0.48 |
| 2025-04-10 | -0.47 |
| 2025-04-09 | -0.48 |
| 2025-04-08 | -0.47 |
| 2025-04-07 | -0.45 |